NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity

Redox Biol. 2024 Apr:70:103060. doi: 10.1016/j.redox.2024.103060. Epub 2024 Feb 1.


There is a complex interrelationship between the nervous system and the cardiovascular system. Comorbidities of cardiovascular diseases (CVD) with mental disorders, and vice versa, are prevalent. Adults with mental disorders such as anxiety and depression have a higher risk of developing CVD, and people with CVD have an increased risk of being diagnosed with mental disorders. Oxidative stress is one of the many pathways associated with the pathophysiology of brain and cardiovascular disease. Nicotinamide adenine dinucleotide phosphate oxidase (NOX) is one of the major generators of reactive oxygen species (ROS) in mammalian cells, as it is the enzyme that specifically produces superoxide. This review summarizes recent findings on the consequences of NOX activation in thrombosis and depression. It also discusses the therapeutic effects and pharmacological strategies of NOX inhibitors in CVD and brain disorders. A better comprehension of these processes could facilitate the development of new therapeutic approaches for the prevention and treatment of the comorbidity of thrombosis and depression.

Keywords: Endothelium; Microglia; NOX; Neurons; Platelets; Psychiatry disorders.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases*
  • Comorbidity
  • Depression / drug therapy
  • Humans
  • Mammals / metabolism
  • NADP / metabolism
  • NADPH Oxidases / metabolism
  • Oxidative Stress
  • Reactive Oxygen Species / metabolism
  • Thrombosis* / drug therapy


  • NADPH Oxidases
  • NADP
  • Reactive Oxygen Species